Armuzzi Alessandro, Pugliese Daniela, Nardone Olga Maria, Guidi Luisa
IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.
Drug Des Devel Ther. 2013 Apr 8;7:289-96. doi: 10.2147/DDDT.S33197. Print 2013.
The treatment of ulcerative colitis has changed over the last decade, with the introduction of biological drugs. This article reviews the currently available therapies for ulcerative colitis and the specific use of these therapies in the management of patients in different settings, particularly the difficult-to-treat patients. The focus of this review is on adalimumab, which has recently obtained approval by the European Medicines Agency and the US Food and Drug Administration, for use in treating adult patients with moderate-to-severe, active ulcerative colitis, who are refractory, intolerant, or who have contraindications to conventional therapy, including corticosteroids and thiopurines. Since the results emerging from the pivotal trials have been subject to some debate, the aim of this review was to summarize all available data on the use of adalimumab in ulcerative colitis, focusing also on a retrospective series of real-life experiences. Taken together, the current evidence indicates that adalimumab is effective for the treatment of patients with different types of ulcerative colitis, including biologically naïve and difficult-to-treat patients.
在过去十年中，随着生物药物的引入，溃疡性结肠炎的治疗发生了变化。本文综述了目前可用的溃疡性结肠炎治疗方法，以及这些疗法在不同情况下（特别是难治性患者）对患者管理的具体应用。本综述的重点是阿达木单抗，它最近已获得欧洲药品管理局和美国食品药品监督管理局的批准，用于治疗中度至重度活动性溃疡性结肠炎的成年患者，这些患者对包括皮质类固醇和硫唑嘌呤在内的传统疗法难治、不耐受或有禁忌证。由于关键试验的结果存在一些争议，本综述的目的是总结关于阿达木单抗在溃疡性结肠炎中应用的所有可用数据，同时也关注一系列回顾性的实际经验。综合来看，目前的证据表明阿达木单抗对治疗不同类型的溃疡性结肠炎患者有效，包括初治患者和难治性患者。
